VESIcare Alternatives Compared
| VESIcare (solifenacin) | Oxybutynin | Myrbetriq (mirabegron) |
|
|---|
| VESIcare (solifenacin) | Oxybutynin | Myrbetriq (mirabegron) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Overactive Bladder, Urinary Incontinence, Urinary Frequency. VESIcare may also be used for purposes not listed in this medication guide. |
Prescription and OTC
Oxybutynin helps to relieve symptoms of an overactive bladder and urinary incontinence but it may cause side effects such as a dry mouth and constipation. Prescribed for Overactive Bladder... View more |
Prescription only
Myrbetriq may be used to relieve symptoms of overactive bladder in adults such as urinary incontinence and urinary frequency. It may also be used to treat the symptoms of neurogenic detrusor... View more |
Related suggestions Urinary Frequency
Urinary Incontinence
Popular comparisons
|
|||||||||||||||||||||||
| More about VESIcare (solifenacin) | More about Oxybutynin | More about Myrbetriq (mirabegron) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
VESIcare has an average rating of 5.6 out of 10 from a total of 142 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 36% reported a negative effect. |
Oxybutynin has an average rating of 6.7 out of 10 from a total of 459 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 24% reported a negative effect. |
Myrbetriq has an average rating of 4.8 out of 10 from a total of 277 ratings on Drugs.com. 34% of reviewers reported a positive effect, while 49% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all VESIcare side effects |
View all Oxybutynin side effects |
View all Myrbetriq side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all VESIcare prices |
View all Oxybutynin prices |
View all Myrbetriq prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other solifenacin brands include: VESIcare LS | Oxytrol, Oxytrol for Women |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
68 hours |
2.3 hours |
50 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 495 drugs are known to interact with VESIcare:
|
A total of 285 drugs are known to interact with Oxybutynin:
|
A total of 249 drugs are known to interact with Myrbetriq:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
November 19, 2004 |
July 16, 1975 |
June 28, 2012 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.